Gary H. Lyman on the Immediate and Long-Term Effects of Febrile Neutropenia

Video

Gary H. Lyman, MD, MPH, Fred Hutchinson Cancer Research Center, discusses the immediate and long-term effects of febrile neutropenia.

Gary H. Lyman, MD, MPH, Fred Hutchinson Cancer Research Center, discusses the immediate and long-term effects of febrile neutropenia.

A study presented at the 2016 ASCO Annual Meeting showed that patients with early-stage breast cancer who experience febrile neutropenia as a result of chemotherapy usually get a reduced relative dose intensity (RDI) for their chemotherapy. Although this usually helps the febrile neutropenia, it often has negative effects down the line, Lyman says.

Modifying or reducing a patient’s chemotherapy dosage has a dramatic effect on the cure and long-term survival rates because of a higher rate of disease recurrence.

Recent Videos
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Related Content
Illustration of small patient and provider characters surrounded by larger technology devices with medical information coming off of the screens and other medical props nearby

Mobile App May Be Feasible for Tracking Oral Cancer Medication Adherence

Bridget Hoyt
March 10th 2025
Article

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Blue rendering of a person with breast tissue highlighted in orange

T-DM1 Further Improves DFS and OS vs Trastuzumab in HER2-Positive Early Breast Cancer

Bridget Hoyt
February 20th 2025
Article

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Simple line illustration of breast tissue on a yellow background

PFS, Tolerability Increase With Lerociclib/Fulvestrant in HR+/HER– Breast Cancer

Roman Fabbricatore
February 10th 2025
Article

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.

Blue diagram of a human's bones and tissue, with the breast tissue and tumor in focus

Pertuzumab Biosimilar BLA for HER2+ Breast Cancer Accepted by FDA

Chris Ryan
February 7th 2025
Article

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.